PET Scan
One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy
International Journal of Molecular Sciences 2023 March 28 [Link] Thomas Hager, Sabrina Borchert, Michael Wessolly, Alexander Mathilakathu, Elena Mairinger, Jens Kollmeier, Thomas Mairinger, Balazs Hegedus, Kristina Greimelmaier, Jeremias Wohlschlaeger, Ken Herrmann, Fabian Dominik Mairinger Abstract Malignant pleural mesothelioma (MPM) is a mainly asbestos-related tumour associated with a very poor prognosis. Therapeutic approaches include multimodal therapy…
Read MoreMalignant Peritoneal Mesothelioma Features Shown by FDG-PET/CT
Cancer Diagnosis & Prognosis 2022 November 3 [Link] Kozo Kuribayashi, Kazuhiro Kitajima, Toshiyuki Minami, Masataka Ikeda, Koichiro Yamakado, Takashi Kijima Abstract Background/aim: Malignant peritoneal meso-thelioma (MPeM) has no specific imaging findings that can distinguish it from other peritoneal tumors and the accuracy of peritoneal cytology is low, therefore definitive diagnosis is usually performed by histology.…
Read MoreFactors affecting the life expectancy in malignant pleural mesothelioma: Our 10 years of studies and experience
Medicine 2022 September 30 [Link] Filiz Cimen, Yetkin Agackiran, Sevim Düzgün, Melike Aloglu, Aysegül Senturk, Sükran Atikcan Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor prognosis. In our study, we aimed to investigate the specific clinical, laboratory, and radiological features of the tumor and the prognostic effect of SUVmax (maximum standardized…
Read MoreFDG PET/CT for Staging and Restaging Malignant Mesothelioma
Seminars in Nuclear Medicine 2022 August 11 [Link] Egesta Lopci, Angelo Castello, Luigi Mansi Abstract Malignant mesothelioma is an aggressive tumor originating from the mesothelial cells and presenting in general with a very poor prognosis. The pleural localization represents the prevailing disease site, while peritoneal involvement is commonly rare. The WHO classifies mesotheliomas into epithelioid,…
Read MoreThrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report
JTO Clinical and Research Reports 2022 June 9 [Link] Takaaki Tanaka, Shoji Asakura, Kazuya Hisamatsu, Nobukazu Fujimoto Abstract A 69-year-old man presented with a pulmonary opacity at a regular medical check-up. He had been exposed to asbestos in a chemical fiber manufacturing setting. Result of positron emission tomography with computed tomography (CT) revealed fluorodeoxyglucose accumulations…
Read MorePrimary malignant pericardial mesothelioma with a survival of 2.5 years: a case report
Translational Cancer Research 2022 May [Link] Yan Yan, Wenli Lv, Yinghao Luo, Jianlin Hu, Jie Yang Abstract Background: Primary malignant pericardial mesothelioma (PMPM) is a highly malignant tumor originating in the pericardium serosum with clinical manifestations presenting as constrictive pericarditis, with pericardial tamponade and heart failure. Malignant pericardial mesothelioma is rare and has a poor…
Read MoreHistology of the pleural rind at [ 18 F]FDG PET/CT hot and cold spots in mesothelioma patients after talc pleurodesis and neoadjuvant chemotherapy
Pathology, Research and Practice 2021 December [Link] Alex Soltermann, Isabelle Opitz, Irene A Burger Abstract The role of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) in evaluating induction chemotherapy in pleural mesothelioma (PM) patients is debated. We compared histology at tumor sites with high versus low [18F]FDG uptake in order to define a morphologic correlate…
Read MoreWhen cardiac surgery comes to its limits: a case report of pericardial mesothelioma invading the myocardium
European Heart Journal Case Reports 2021 July 7 [Link] Leo Pölzl, Jakob Hirsch, Agnes Mayr, Christian Uprimny, Georg Oberhuber, Hansjörg J Zwick, Ludwig Müller, Gerhard Pölzl Abstract Background: Primary pericardial mesothelioma (PPM) is a rare form of highly aggressive cancer. Many patients are diagnosed only at an advanced stage. Therefore, the overall survival rate is…
Read MoreDeep learning with deep convolutional neural network using FDG-PET/CT for malignant pleural mesothelioma diagnosis
Oncotarget 2021 June 18 [Link] Kazuhiro Kitajima, Hidetoshi Matsuo, Atsushi Kono, Kozo Kuribayashi, Takashi Kijima, Masaki Hashimoto, Seiki Hasegawa, Takamichi Murakami, Koichiro Yamakado Abstract Objectives: This study analyzed an artificial intelligence (AI) deep learning method with a three-dimensional deep convolutional neural network (3D DCNN) in regard to diagnostic accuracy to differentiate malignant pleural mesothelioma (MPM)…
Read MoreResponse to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT
Cancers 2021 March 4 [Link] Kazuhiro Kitajima, Mitsunari Maruyama, Hiroyuki Yokoyama, Toshiyuki Minami, Takashi Yokoi, Akifumi Nakamura, Masaki Hashimoto, Nobuyuki Kondo, Kozo Kuribayashi, Takashi Kijima, Seiki Hasegawa, Koichiro Yamakado Abstract Background: To compare three FDG-PET criteria (EORTC, PERCIST, imPERCIST) with CT criteria (combined modified RECIST and RECIST 1.1) for response evaluation and prognosis prediction in…
Read More